	Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). Mult Scler Tallantyre EC, Planchon SM, Howard H, Mays J, Frowd N, Cohen JA, Coles A, Hersh CM, Miller DM, Dever M, Gray EH, LaRocca NG, Nakamura K, Bale C, Covey-Crump G, Alvarez E, Arun T, Brownlee WJ, Craner M, Freeman L, Frost N, Goldman MD, Gupta RK, Harding KE, Hobart J, Hutton GJ, Hyland MH, Kalra S, Kannan M, Kantarci O, Lashley D, Lily O, Mahad D, Nicholas JA, Nicholas R, Paling D, Pearson OR, Rice CM, Samudralwar R, Schmalstieg WF, Singh M, Zune The E, Weinstock-Guttman B, Zabeti A, Love TE, Gunzler DD, Liu Y, Gerry S, Evangelou N, Ontaneda D. PMID: 42218617 [PubMed - as supplied by publisher]
	An Exploratory Cross-Sectional Study of the Association Between Regular Cigarette Smoking and Level of Disability, Hand Dexterity, Cognitive Impairment, Fatigue, and Markers of Oxidative Stress in Male Patients With Relapsing-Remitting Multiple Sclerosis. Am J Mens Health Ahmadi Bonabi M, Mosaddeghi-Heris R, Taheri N, Talebi M, Naseri A. PMID: 42218574 [PubMed - indexed for MEDLINE]
	Multikingdom microbiome-based machine learning enables multiple sclerosis diagnosis. NPJ Biofilms Microbiomes Zhu G, Yang G. PMID: 42218218 [PubMed - as supplied by publisher]
	Benefits of 12-week self-paced training combined with melatonin supplementation on oxidative stress, inflammation, hyperlipidemia, and body composition in multiple sclerosis patients: a randomized controlled trial. Brain Res Bull Jallouli S, Jallouli D, Kallel C, Sakka S, Damak M, Jaafar B, Mhiri C, de Marco G, Driss T, Ayadi F, Hammouda O. PMID: 42217742 [PubMed - as supplied by publisher]
	A more optimistic outlook about disease-modifying therapies and depressive symptoms in multiple sclerosis: A cross-sectional analysis. J Affect Disord Freedman DE, Oh J, Feinstein A. PMID: 42217643 [PubMed - as supplied by publisher]
	Correlation of cerebrospinal fluid and serum markers with EDSS-assessed baseline disability in multiple sclerosis patients. Mult Scler Relat Disord Wang F, Zhang S, Xie X, Qin B, Huang W. PMID: 42217432 [PubMed - as supplied by publisher]
	Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review. Mult Scler Relat Disord Azeem MH, Shakeel R, Hassan D, Ahmed SR, Fatima A, Manjee KZ, Silat L, Abdulgadir A, Hussain A, Sajid EU, Arshad T. PMID: 42217431 [PubMed - as supplied by publisher]
	Early Versus Delayed Treatment with Ocrelizumab: A Multicenter, Real-World Observational Study in People with Multiple Sclerosis. Neurol Ther Alvarez E, Naismith RT, Hua LH, Pineda ED, Romdhani H, Guérin A, Lévesque-Leroux M, Marathe G, Nakamura K, Ontaneda D. PMID: 42217095 [PubMed - as supplied by publisher]
	Dance for health impact in a rural Scottish island community: understanding stakeholder experiences. Health Promot Int Davis E, Whiteside B, Stott T, Paul L. PMID: 42216838 [PubMed - indexed for MEDLINE]
	Machine learning-based identification of multidimensional predictors of quality of life in individuals with multiple sclerosis. Medicine (Baltimore) Yeti, Canli M, Canli , Kocaman H, Yildirim H, Yildiz NT, Duran S. PMID: 42216334 [PubMed - indexed for MEDLINE]
	Association between emotion recognition and cognitive functioning in multiple sclerosis: a multilevel correlational meta-analysis. Sci Rep Degraeve B, Henry A, Lenne B. PMID: 42215611 [PubMed - as supplied by publisher]
	Neurodegenerative and inflammatory biomarkers are detectable in saliva in multiple sclerosis. Sci Rep Castelli B, Shapoori S, McMahon JM, Das K, Bocanegra-Lopez AP, Moosavizadeh S, Counihan B, Pandit A, FitzGerald U. PMID: 42215518 [PubMed - as supplied by publisher]
	From emergency myelopoiesis to chronic myeloid reprogramming: hematopoietic dysregulation in multiple sclerosis. Rev Neurosci Gu L, Ding L, Gu Z, Shi Q, Ren Y, Zhu H. PMID: 42215013 [PubMed - as supplied by publisher]
	Cognitively stimulating activities in multiple sclerosis: Results of a randomized controlled trial. Mult Scler Relat Disord Færk AK, Sellebjerg F, Lund JL, Loft M, Chow HH, Marstrand L. PMID: 42214251 [PubMed - as supplied by publisher]
	Psychological resilience as a behavioral proxy for cognitive reserve in multiple sclerosis: A theoretical reappraisal. Mult Scler Relat Disord Broche-Pérez Y. PMID: 42214249 [PubMed - as supplied by publisher]
	Building sustainable multiple sclerosis registries in Latin America: A practical framework for real-world evidence generation and healthcare access. Mult Scler Relat Disord Rojas JI, Patrucco L, Cristiano E, Becker J, Giunta DH. PMID: 42214248 [PubMed - as supplied by publisher]
	Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability. Neurology Sharmin S, Roos I, Labauge PM, Filippi M, Lebrun-Frenay C, Iaffaldano P, Simone M, Perini P, Magy L, Van Der Walt A, Butzkueven H, Manchon E, Alroughani R, Patti F, Pozzilli C, Eichau S, Morra VB, Laplaud DA, Maimone D, Portaccio E, Trojano M, Amato MP, Deiva K, Vukusic S, Kalincik T, MSBase, OFSEP, and Italian Multiple Sclerosis Registry Investigators. PMID: 42214041 [PubMed - indexed for MEDLINE]
	Targeting the microbiome-NLRP3-ferroptosis axis in multiple sclerosis: Neuropharmacological implications for microglial dysfunction and demyelination. Neuropharmacology Fawzy MN, Abdelaziz AM, Shokr MM, Fathy MK. PMID: 42208757 [PubMed - as supplied by publisher]
	Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. Lancet Giovannoni G, Airas L, Bove R, Cutter GR, Czarnecki M, Drulovic J, Hobart J, Kuhle J, Montalban X, Selmaj KW, Tur C, Wolinsky JS, Baldinotti A, Bonati U, Craveiro L, Giacobino C, Manfrini M, Schneble HM, Stevenson P, Wang Q, Yang K, Oh J, ORATORIO-HAND study group. PMID: 42208561 [PubMed - indexed for MEDLINE]
	Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. Lancet Hauser SL, Giovannoni G, Montalban X, Oh J, Bar-Or A, Sormani MP, Weber MS, Stoll S, Nicholas JA, Nehrych T, Bonek R, Selmaj K, Maciejowski M, Zecevic D, Raposo C, Owen R, Bonati U, Madjar K, Harfst E, Wang Q, Raievska A, Manfrini M, Schneble HM, Kappos L, MUSETTE and GAVOTTE Study Groups. PMID: 42208560 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 44120

Page 1 of 2206



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy